Teva Faces Legal Setback as European Court Rejects Appeal Against Cephalon's Antitrust Fine

In a significant blow to pharmaceutical giant Teva, the European Union's Court of Appeal has dismissed the company's appeal against a substantial fine imposed on its wholly owned subsidiary, Cephalon. The fine, totaling 60 million euros, was initially imposed by the European Union in November 2020 following a nine-year investigation that revealed Cephalon's violation of antitrust laws.

The investigation unearthed a controversial practice known as "Pay for Delay," where Cephalon allegedly made cash payments to its competitors, including Teva, during the period between 2005 and 2011. These payments were made to delay the launch of generic versions of Cephalon's flagship drug, Provigil, which is used to treat excessive sleepiness associated with narcolepsy, shift work, and sleep apnea caused by upper airway obstruction.

The essence of "Pay for Delay" is to extend the monopoly of the original drug developer, ensuring an extended period of high profits while compensating generic drug manufacturers for not entering the market sooner. Unfortunately, the burden of this practice falls on medical insurance companies and consumers, who end up paying inflated prices for the medication.

Teva had already anticipated the financial impact of this legal dispute, making a provision in its balance sheet to cover the potential loss. Additionally, the company provided the European Union with a bank guarantee to ensure payment of the imposed fine.

It's worth noting that Teva had acquired Cephalon for a substantial sum of $6.8 billion back in October 2011, a move that significantly expanded its pharmaceutical portfolio.

In response to the Court of Appeal's decision, Teva's spokesperson, Maveev, expressed disappointment, stating, "Today's decision is disappointing. Teva is examining it and examining all the options open to it. Teva has defended its position in good faith and is committed to conducting its business in accordance with the law and providing medicines at fair prices to millions of people every day. The European Union investigation will not divert Teva from its mission."

Teva now faces the financial consequences of this legal setback and will need to explore its options moving forward. This case highlights the ongoing challenges in the pharmaceutical industry surrounding antitrust violations and their impact on pricing and competition within the market.